Tag: Pharmaceutical Technology Award

Yan Niu | Pharmaceutical Science | Research Excellence Award

Published on by WSA Awards

Prof. Yan Niu | Pharmaceutical Science | Research Excellence Award

Peking University | China

Prof. Yan Niu is a medicinal chemist at Peking University whose research focuses on the discovery and optimization of biologically active small molecules, with special emphasis on hydrophobic tagging–based targeted protein degradation. She has contributed significant advances in amino-acid–derived hydrophobic tags capable of inducing selective POI degradation with mechanisms and pharmacological profiles distinct from PROTACs, expanding the chemical space available for next-generation degraders. With 47 Scopus-indexed publications, 549 citations, and an h-index of 14, her work bridges synthetic chemistry, chemical biology, and drug discovery. She has led competitive national projects, filed three patents, and collaborated internationally in Germany and Austria. Her research provides promising strategies for developing novel therapeutics and deepens mechanistic understanding of protein degradation pathways, contributing to innovation in medicinal chemistry and early-stage drug development.

Citation Metrics (Scopus)

500
450
300
150
0

Citations
549
Documents
47
h-index
14

Citations

Documents

h-index

Featured Publications

 

Omid Mehrpour | Pharmaceutical Science | Editorial Board Member

Published on by WSA Awards

Dr. Omid Mehrpour | Pharmaceutical Science | Editorial Board Member

Wayne State University | United States

Dr. Omid Mehrpour is a distinguished medical toxicologist, clinical data scientist, and physician whose work integrates toxicology, public health, and artificial intelligence to advance diagnostic accuracy and patient outcomes. With over two decades of academic, clinical, and research experience, he has become an internationally recognized expert in poisoning, substance use disorders, and AI-driven medical decision-making. Dr. Mehrpour has authored more than 200 peer-reviewed articles, ten book chapters, and a book translation, accumulating over 4,000 scientific citations. His publications and research outputs have significantly shaped clinical toxicology guidelines globally, particularly in areas related to opioids, heavy metals, aluminum phosphide, cannabinoids, and environmental toxicants. A pioneer in AI-based diagnostic innovation, Dr. Mehrpour developed machine learning–driven protocols for poison diagnosis, leading to two registered U.S. patents and additional patents in Iran for diagnostic software and toxicology devices. His work at the Rocky Mountain Poison & Drug Safety Center and collaborations with national databases such as NPDS and ToxIC contributed foundational methods for rapid identification and triage of poisoning cases. He has also led AI and clinical informatics initiatives at the University of Colorado Anschutz Medical Campus and founded AI and Health LLC to develop intelligent clinical tools that enhance diagnosis and care delivery. Throughout his career, Dr. Mehrpour has held leadership roles including Head of the Medical Toxicology and Drug Abuse Research Center and Director of the Poisoning Ward at Birjand University of Medical Sciences. He has supervised numerous graduate researchers and served on editorial boards of multiple international journals. His contributions have received global recognition, including placement among the top 2% of scientists worldwide, multiple “Top Reviewer” honors from Publons, and numerous national research awards. Dr. Mehrpour’s work continues to elevate the fields of toxicology, predictive modeling, and precision medicine, contributing impactful solutions that improve healthcare systems and advance patient safety worldwide.

Profiles: Scopus | ORCID

Featured Publications

1. Eizadi-Mood, N., Barzam, E., Pirali, Z., Feizi, A., Namvar, M., Abdi, E., Mirmoghtadaee, P., Mehrpour, O., & Meamar, R. (2025). Gender differences in opioid and stimulant poisoning in the central region of Iran: A cross-sectional study. Scientific Reports.

2. Amrollahi-Sharifabadi, M., Oladejo, T. O., Ibrahim, A. S., Shakoor, B., Mehrpour, O., Sadeghi-Hashjin, G., & Gonçalves, S. (2025). Melatonin’s paradox: From therapeutic benefits to toxicity warnings. Chemico-Biological Interactions, 111556.

3. Kooshki, A., Mansouri, B., Farmani, R., Amirabadizadeh, A., Mehrpour, O., Sanjari, M. J., & Nakhaee, S. (2024). Essential and toxic metal concentrations in biological samples of multiple sclerosis patients: A systematic review and meta-analysis. PLOS ONE, 19(12), e0313851.

4. Mehrpour, O., & Sadeghi, M. (2024). The occurrence of unusually cold weather could contribute to the incidence of carbon monoxide poisoning. Clinical and Experimental Emergency Medicine.

5. Nakhaee, S., Kooshki, A., Hormozi, A., Akbari, A., Mehrpour, O., & Farrokhfall, K. (2023). Cinnamon and cognitive function: A systematic review of preclinical and clinical studies. Nutritional Neuroscience.

Ismaeil Haririan | Pharmaceutical Biomaterials | Outstanding Scientist Award

Published on by WSA Awards

Prof. Ismaeil Haririan | Pharmaceutical Biomaterials | Outstanding Scientist Award

Teharn University of Medical Sciences (TUMS), Iran

Prof. Ismaeil Haririan is a distinguished Professor of Pharmaceutics and Pharmaceutical Biomaterials at the Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS), where he also serves as the Founder of the Department of Pharmaceutical Biomaterials and Head of the Biomaterials Research Center. He earned his Pharm.D. from Tabriz University and pursued a Ph.D. in Pharmaceutics at the University of London in 1993, followed by postdoctoral research in targeted drug delivery, which laid the foundation for his lifelong contributions to biomaterials and regenerative medicine. With over three decades of academic and research experience, Prof. Haririan has played a pioneering role in advancing interdisciplinary research that integrates pharmacy, materials science, and biomedical engineering. His research interests span the design of hyaluronic acid hydrogels for bone and cartilage regeneration, 3D pharming and bioprinting, microfluidics in pharmaceutical applications, drug delivery systems, nanomedicine, and pharmaceutical rheology. He has authored more than 120 SCI-indexed articles, earning over 3,600 citations, an h-index of 34, and an i10-index of 65, reflecting the global impact of his work. His research skills extend across tissue engineering, drug delivery system design, nanostructure characterization, and translational medicine, complemented by his strong expertise in mentoring doctoral candidates and industrial trainees. Recognized internationally as a leading figure in pharmaceutical biomaterials, Prof. Haririan has received numerous awards and honors, including recognition as a world leader in bioprinting research between 2022 and 2025. Beyond his scholarly contributions, he has served in editorial capacities, led major research collaborations, and advanced education by supervising Pharm.D. and Ph.D. students. In conclusion, Prof. Haririan embodies academic excellence, visionary leadership, and innovative research, making him one of the most influential scientists in pharmaceutics and biomaterials whose work continues to inspire progress in regenerative medicine and pharmaceutical sciences worldwide.

Profile: Scopus | ORCID

Featured Publications

Al-Jawadri, A. M. H., Karami, Z., Haririan, I., Akrami, M., & Gholami, M. (2025). Development of a bio-inspired phagocytic stable nanoghost with anti-inflammatory properties for management of inflammation in ulcerative colitis. Journal of Drug Targeting, 33(7), 1-15.

Safari, F., Goudarzi, A., Abolghasemi, H., Mohammad, H. A., Akrami, M., Mohammadi, S., & Haririan, I. (2025). Additive manufacturing of regorafenib tablets: Formulation strategies and characterization for colorectal cancer. Polymers, 17(17), 2302.

Sohrabi, R., Miri, A. H., Rad-Malekshahi, M., Saadatpour, F., Pourjabbar, B., Keshel, S. H., Arefian, E., Balalaei, S., Masoumi, A., Khalili, F., Haririan, I., Akrami, M., & Shahriari, M. H. (2025). Corrigendum to “Development of silk fibroin/collagen film containing GI-20 peptide-loaded PLGA nanoparticles against corneal herpes simplex virus-1” [International Journal of Pharmaceutics, 669 (2025), 125022]. International Journal of Pharmaceutics, 674, 125369.

Torabi, M., Haririan, I., Foroumadi, A., Ghanbari, H., & Ghasemi, F. (2024). A deep learning model based on the BERT pre-trained model to predict the antiproliferative activity of anti-cancer chemical compounds. SAR and QSAR in Environmental Research, 35(11), 971-992

Cem Calışkan | Pharmaceutical Science | Best Researcher Award

Published on by WSA Awards

Dr. Cem Calışkan | Pharmaceutical Science | Best Researcher Award

R&D Manager from World Medicine, Turkey

Dr. Cem Çalışkan is an accomplished R&D Manager and pharmaceutical researcher with a distinguished background in analytical chemistry, method development, and regulatory compliance. His professional journey is marked by extensive contributions to the pharmaceutical industry, particularly in analytical method validation, formulation development, and laboratory accreditation processes. With over a decade of progressive experience, Dr. Çalışkan has held key roles at leading pharmaceutical organizations including World Medicine and Neutec İlaç, consistently driving innovation and excellence in pharmaceutical R&D. His academic background features a Ph.D. in Analytical Chemistry from Yıldız Technical University, complemented by a Master’s degree in Organic Chemistry and ongoing Executive MBA studies at Istanbul University, reflecting a multidisciplinary approach to science and leadership. Dr. Çalışkan’s portfolio includes several peer-reviewed publications in top scientific journals, where he explores themes such as nitrosamine detection, impurity profiling, stability-indicating methods, and in-vitro drug release. His research not only addresses critical analytical challenges but also aligns with global regulatory standards. With a passion for mentoring, scientific rigor, and innovation, Dr. Çalışkan exemplifies the integration of academic excellence and industrial impact, making him a strong candidate for scientific recognition at the international level.

Professional Profile

Education

Dr. Cem Çalışkan has a comprehensive and interdisciplinary educational background that has shaped his expertise in analytical and organic chemistry as well as pharmaceutical development. He earned his Doctor of Philosophy (Ph.D.) in Analytical Chemistry from Yıldız Technical University between 2018 and 2022, where he focused on advanced analytical techniques and pharmaceutical applications. His doctoral work provided the foundation for several high-impact scientific publications and patents in method validation and impurity analysis. To complement his scientific expertise with managerial insight, Dr. Çalışkan is currently pursuing an Executive MBA at Istanbul University (2024–present), focusing on strategic business management and leadership in the pharmaceutical industry. His academic journey also includes a Master of Science in Organic Chemistry from Sakarya University (2014–2016), where he deepened his understanding of chemical reactions, drug formulation, and molecular mechanisms. He holds a Bachelor of Science in Chemistry from Uludağ University (2003–2009), which laid the initial groundwork for his professional path in R&D. This strong academic progression, spanning both the sciences and management, enables Dr. Çalışkan to bridge the gap between innovative research and strategic decision-making in the pharmaceutical sector.

Professional Experience

Dr. Cem Çalışkan’s professional experience reflects a sustained commitment to innovation and quality in pharmaceutical research and development. Since 2020, he has been serving as the R&D Manager at World Medicine, where he leads cross-functional teams in analytical development, method validation, and compliance with international regulatory standards. In this role, he initiated the patented WMINOLAB analytical service model, exemplifying his vision for high-quality, independent R&D frameworks. Prior to this, from February to August 2020, he held the position of R&D Analytical Development Chief at the same organization, coordinating sustainable business process models, documentation systems, and team development initiatives. Between 2013 and 2020, Dr. Çalışkan worked as an R&D Responsible Specialist, playing a critical role in analytical method development, stability testing, and responding to regulatory queries from global authorities. Earlier in his career, he served as a Process Development Analyst at Neutec İlaç (2011–2013), where he conducted formulation trials, transfer validations, and documentation for CTD Module III. These roles have not only honed his technical capabilities but also highlighted his strategic thinking, regulatory insight, and project management skills in both domestic and international pharmaceutical landscapes.

Research Interests

Dr. Cem Çalışkan’s research interests center on pharmaceutical analytical chemistry, with a special focus on developing novel methods for impurity profiling, drug stability studies, and nitrosamine risk assessment. He is deeply engaged in creating robust and regulatory-compliant analytical methodologies using cutting-edge instruments such as LC-MS/MS, RP-HPLC, and FTIR spectroscopy. His scientific inquiries aim to improve the accuracy, reproducibility, and efficiency of pharmaceutical testing methods, ensuring safer and more effective drug formulations. A key area of his work involves validating stability-indicating methods for various drug compounds, exploring the physicochemical behavior of active pharmaceutical ingredients (APIs) and excipients under stress conditions. He is also involved in studies on in-vitro drug release, polymer membrane permeability, and analytical compatibility of formulation components. In recent years, Dr. Çalışkan has broadened his scope to include the assessment of genotoxic impurities and packaging-related contaminant analysis, which are critical in modern pharmaceutical safety regulations. His interest in bridging laboratory innovation with regulatory frameworks is reflected in his leadership of accredited research labs and method development teams. This intersection of research excellence and industry relevance defines his contribution to the evolving landscape of pharmaceutical sciences.

Research Skills

Dr. Cem Çalışkan possesses a broad and advanced skill set in pharmaceutical R&D, particularly in the analytical domain. His technical proficiency includes the use of LC-MS/MS, RP-HPLC, FTIR, UV-Vis spectroscopy, and gravimetric analysis for method development, validation, and impurity determination. He is well-versed in Good Laboratory Practice (GLP) and has led numerous method validation studies, including for high-risk pharmaceutical substances like nitrosamines and complex impurities. His skills extend to process optimization, formulation compatibility testing, and the analytical transfer of drug products across laboratories and regulatory environments. Dr. Çalışkan also excels in scientific documentation, protocol writing, and preparation of CTD Module III files for regulatory submission. Beyond technical expertise, he has notable experience in project management, cross-departmental coordination, and team training, equipping him to lead dynamic research teams. His communication skills support effective regulatory correspondence with ministries and international partners, while his analytical thinking aids in critical decision-making across all stages of pharmaceutical development. Combined, these research skills make him not only a technically sound researcher but also an effective scientific leader.

Awards and Honors

While specific awards and honors are not listed in his current profile, Dr. Cem Çalışkan’s career accomplishments reflect a reputation for research excellence and industrial innovation. His leadership in the development and implementation of WMINOLAB, a patented analytical service platform within World Medicine, stands as a testament to his ability to deliver novel, scalable solutions to industry-wide challenges. His publications in reputable journals such as the Journal of Pharmaceutical Sciences, European Journal of Mass Spectrometry, and Journal of AOAC International showcase his academic influence and contributions to pharmaceutical quality control and safety. Additionally, Dr. Çalışkan has played a crucial role in securing and maintaining laboratory accreditations, further evidencing his standing in the professional R&D community. With continued recognition through publications, cross-functional leadership roles, and innovation in analytical techniques, it is evident that he is well-positioned for formal accolades in both industrial and academic circles. Nomination for a Best Researcher Award would be a fitting acknowledgment of his significant impact on pharmaceutical research and method validation at both national and international levels.

Conclusion

Dr. Cem Çalışkan represents a compelling candidate for the Best Researcher Award, bringing together scientific rigor, innovative thinking, and impactful leadership in the pharmaceutical sector. His multi-tiered education, from chemistry through analytical science to business management, empowers him to operate effectively at the intersection of research, industry, and regulation. His extensive experience with analytical method development, impurity profiling, and compliance documentation, along with his proactive approach to laboratory innovation, positions him as a distinguished researcher. His publication record reinforces his scientific credibility, while his managerial roles highlight his ability to lead R&D initiatives with strategic foresight. What sets Dr. Çalışkan apart is not only his technical excellence but also his drive to elevate pharmaceutical research standards in Turkey and beyond. As the industry faces increasing regulatory scrutiny and demands for innovation, his skill set is more relevant than ever. Recognizing his achievements through a Best Researcher Award would honor a career dedicated to advancing analytical science and fostering pharmaceutical innovation, while inspiring emerging researchers to pursue excellence in both academia and industry.

Publications Top Notes

1. Comparison of permeability of topical Cream drug through polymer synthetic membranes of different structures using Franz Cell diffusion test

  • Authors: Cihan Torlak, Müge Güleli, Şevki Kızılok, Remziye Azra Kartop, et al.

  • Year: 2024

  • Journal: Journal of Dispersion Science and Technology

2. Evaluation of a Novel LC‑MS/MS Based Analytical Method for the Risk Assessment of Nitrosamines in Pharmaceutical Products and Packaging Materials

  • Authors: Remziye Azra Kartop, Cihan Torlak, et al. (study led by Kartop and colleagues)

  • Year: 2024

  • Journal: Journal of Pharmaceutical Sciences

3. Simultaneous quantification of tiotropium bromide impurities G + H in capsule formulation by LC‑MS/MS

  • Authors: Not specified in preview

  • Year: 2023

  • Journal: European Journal of Mass Spectrometry

 

 

Sa Xiao | Pharmaceutical Science | Best Researcher Award

Published on by WSA Awards

Dr. Sa Xiao | Pharmaceutical Science | Best Researcher Award

Chief Pharmacist, Clinical pharmacist from The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, China

Sa Xiao is an experienced Clinical Pharmacist currently working at the Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, Guangdong, China. she has dedicated her career to clinical pharmacy with a focus on providing quality patient care and optimizing pharmaceutical practices. Sa Xiao holds a Master’s degree in Pharmacology and a Bachelor’s degree in Pharmaceutical Engineering. Over the past five years and seven months, she has consistently contributed to clinical pharmacy, focusing on improving therapeutic outcomes and pharmaceutical interventions. Sa Xiao’s role places her at the intersection of clinical application and pharmaceutical research, where she works to enhance drug therapy effectiveness and patient safety. Her work contributes directly to hospital-based pharmaceutical care and supports interdisciplinary collaboration in medical settings. Sa Xiao’s background equips her with both theoretical knowledge and practical clinical experience, positioning her as a valuable asset in the healthcare system. While her current profile emphasizes her clinical expertise, expanding her research portfolio could further elevate her impact in the pharmaceutical field. Her dedication, professional growth, and potential for further research contributions make her a promising candidate for recognition in her domain.

Professional Profile

Education

Sa Xiao has built a strong academic foundation that supports her professional excellence in clinical pharmacy. She began her higher education journey at Huzhou Normal University, where she pursued a Bachelor’s degree in Pharmaceutical Engineering from September 2012 to June 2016. This program provided her with essential knowledge of pharmaceutical sciences, drug formulation, and pharmaceutical manufacturing processes. Her education at this stage focused on understanding drug properties, production, and the basic principles that guide pharmaceutical development. After completing her undergraduate studies, Sa Xiao advanced her academic qualifications by enrolling in Guangdong Medical University, where she earned her Master’s degree in Pharmacology from September 2016 to June 2019. This graduate program allowed her to delve deeper into the study of drug actions, mechanisms, and pharmacokinetics. Through her Master’s studies, she developed a comprehensive understanding of clinical pharmacology, which now directly supports her work as a clinical pharmacist. Both her degrees are recognized by the Ministry of Education, China, affirming the academic rigor and credibility of her educational background. Her academic journey demonstrates a seamless transition from pharmaceutical engineering to clinical application, providing her with the necessary expertise to excel in both pharmaceutical sciences and patient-centered clinical practice.

Professional Experience

Sa Xiao has gained substantial professional experience as a Clinical Pharmacist, holding this role since July 2019 at the Department of Pharmacy, The Sixth Affiliated Hospital, School of Medicine, South China University of Technology. With over five years of experience, she has developed a deep understanding of clinical pharmacy operations, patient care protocols, and hospital pharmaceutical services. Her responsibilities likely include reviewing prescriptions, optimizing medication therapies, ensuring the safe and effective use of drugs, and collaborating with medical teams to enhance patient outcomes. Working in a hospital affiliated with a reputable university has provided her with exposure to clinical research, medical education, and interdisciplinary cooperation. Sa Xiao’s experience is not limited to routine pharmacy tasks; her role also requires ongoing learning and adaptation to the latest pharmaceutical guidelines and therapeutic advancements. Her career has been characterized by dedication to improving patient care and supporting evidence-based clinical decisions. While her profile currently focuses on clinical responsibilities, there is potential for her to expand her contributions to include scientific publications, research studies, and leadership in pharmaceutical innovations. Her professional track record reflects commitment, consistency, and the ability to thrive in a demanding healthcare environment.

Research Interest

Sa Xiao’s research interests are rooted in clinical pharmacy and pharmacology, with a focus on optimizing drug therapies, enhancing patient safety, and improving pharmaceutical care within hospital settings. Her academic and professional background suggests a strong interest in therapeutic drug monitoring, drug interactions, and evidence-based medication management. She is likely driven to explore methods for improving the clinical efficacy of pharmacological treatments and minimizing adverse drug reactions. Additionally, she may be interested in research concerning personalized medicine, dosage adjustments for specific patient populations, and clinical outcomes related to pharmaceutical interventions. Her experience as a clinical pharmacist positions her to contribute valuable insights into hospital-based drug management, prescription review processes, and the practical challenges faced in clinical settings. Future research could also include comparative studies on the effectiveness of different pharmacological treatments and the implementation of clinical pharmacy protocols to improve patient care. By aligning her clinical expertise with focused research initiatives, Sa Xiao has the potential to contribute to both national and international discussions in the field of clinical pharmacology and pharmacy practice. Expanding her research interests to cover these areas would significantly strengthen her academic and professional profile.

Research Skills

Sa Xiao possesses a range of research skills that align with her clinical pharmacy background. Her academic training in pharmacology provided her with expertise in drug action mechanisms, pharmacokinetics, and pharmacodynamics, which are essential for conducting clinical pharmaceutical research. She likely has experience in analyzing clinical data, reviewing case studies, and evaluating therapeutic outcomes in real-world settings. Her role as a clinical pharmacist has refined her skills in prescription auditing, patient counseling, and drug therapy evaluation, which contribute to her ability to design practical, patient-focused research projects. Sa Xiao is also expected to be proficient in using clinical databases, medical literature review systems, and pharmacovigilance tools to support her clinical decision-making and potential research activities. Moreover, she may have developed collaborative skills through working with interdisciplinary teams, which are critical for conducting joint clinical studies and implementing hospital-wide pharmaceutical protocols. To further enhance her research portfolio, acquiring advanced skills in statistical analysis, research methodology, and scientific writing would be beneficial. By building on her current skill set and actively participating in research dissemination through conferences and publications, Sa Xiao can establish herself as a leading contributor in the clinical pharmacy research community.

Awards and Honors

At present, no specific awards or honors have been provided for Sa Xiao. However, her sustained commitment to clinical pharmacy over a period of more than five years at a leading university hospital reflects her professional reliability and growing expertise. Although formal recognitions such as research awards, clinical excellence distinctions, or academic honors have not yet been documented, Sa Xiao’s continuous role in a competitive healthcare environment signifies institutional trust in her capabilities. It is possible that she has received internal recognition for her contributions to patient care, medication management, or quality improvement initiatives within her department. Engaging in national or international pharmaceutical competitions, participating in recognized clinical research projects, and contributing to peer-reviewed publications could open avenues for future awards and honors. Earning formal recognition would not only validate her contributions but also help strengthen her professional profile for broader scientific and clinical acknowledgment. Sa Xiao’s consistent career growth and practical impact within the hospital setting suggest that she is well-positioned to achieve significant honors as she continues to expand her involvement in clinical research and professional development activities in the future.

Conclusion

In conclusion, Sa Xiao is a highly capable clinical pharmacist with a strong educational background and valuable experience in the hospital pharmaceutical sector. Her work at The Sixth Affiliated Hospital, School of Medicine, South China University of Technology demonstrates her ability to apply pharmacological knowledge in a clinical environment, directly benefiting patient care and therapeutic practices. While her current profile is predominantly clinical, there is significant potential for her to make substantial research contributions to the field of clinical pharmacy and pharmacology. Sa Xiao’s foundation in pharmaceutical engineering and pharmacology equips her with both theoretical and practical expertise, which can be further advanced through scientific publications, conference presentations, and research collaborations. By actively participating in research dissemination and seeking broader recognition through professional awards, she can enhance her influence within the scientific and medical communities. Sa Xiao’s dedication, clinical precision, and future research potential position her as an emerging contributor to the advancement of pharmaceutical care and clinical pharmacy research. With further academic engagement and research output, she is likely to achieve greater professional recognition and make impactful contributions to the global healthcare landscape.

Publications Top Notes

1. Depression and Suicide/Self-Injury Signals for Weight Loss Medications: A Disproportionality Analysis of Semaglutide, Liraglutide, and Tirzepatide in FAERS Database

  • Journal: Journal of Affective Disorders

  • Publication Date: 2025-06-14

  • Authors: Wang M, Yang Z, Yan M, Liu S, Xiao S

2. Protective Effects of Aqueous Extract of Wampee Fruit Against Anti-Tubercular Drug-Induced Hepatotoxicity in Rats

  • Journal: Journal of Biological Regulators and Homeostatic Agents

  • Publication Date: 2019-01-01

  • Authors: Guan TM, Xiao S, Liu DC, Liao XH, Li WD, Wu KF, Huang R

 

Carolina Batista | Pharmaceutical Science | Women Researcher Award

Published on by WSA Awards

Dr. Carolina Batista | Pharmaceutical Science | Women Researcher Award

Biomedical from Federal University of Rio de Janeiro, Brazil

Dr. Carolina Batista is a distinguished global health physician with over two decades of experience in humanitarian and public health initiatives. Currently serving as the Head of Global Health Affairs at Baraka Impact Finance, she leverages her medical expertise and strategic insight to foster innovative health solutions for underserved populations. Her career commenced in Brazil, where she provided medical care to indigenous communities in the Amazon. In 2007, she joined Médecins Sans Frontières (MSF), undertaking assignments in Somalia, Africa, and Latin America, focusing on neglected tropical diseases (NTDs) and emerging infectious diseases. As Director of MSF’s Brazilian Medical Unit, she led international campaigns, notably for Chagas disease. Subsequently, at the Drugs for Neglected Diseases initiative (DNDi), she spearheaded access frameworks for NTDs across Latin America, influencing public policies and fostering partnerships. Dr. Batista holds a medical degree from Brazil and a master’s in International Public Health from institutions including the Swiss Tropical and Public Health Institute. Her contributions extend to roles on the International Board of MSF, The Lancet COVID-19 Commission, and as a strategic advisor for ISGlobal, reflecting her commitment to health equity and innovation in global health.

Professional Profile

Education

Dr. Carolina Batista’s educational journey is marked by a blend of clinical training and global public health expertise. She earned her medical degree in Brazil, grounding her in clinical practice and primary healthcare delivery. Pursuing a broader impact, she obtained a master’s degree in International Public Health through a collaborative program involving the Swiss Tropical and Public Health Institute, the Institute of Tropical Medicine in Antwerp, and the Royal Tropical Institute in Amsterdam. This multidisciplinary education equipped her with a comprehensive understanding of global health challenges, particularly in infectious and neglected diseases. Further enhancing her capabilities, Dr. Batista pursued advanced studies in management, health and human rights, and policy and advocacy from renowned institutions. This diverse educational background has been instrumental in her ability to design and implement effective health interventions and policies across various international contexts.

Professional Experience

Dr. Carolina Batista’s professional trajectory encompasses significant roles in global health organizations. Her career began in Brazil, providing medical care to indigenous communities in the Amazon. In 2007, she joined Médecins Sans Frontières (MSF), undertaking assignments in Somalia and later serving as Director of the Brazilian Medical Unit, focusing on neglected tropical diseases (NTDs) and emerging infectious diseases. She led international campaigns, notably for Chagas disease, and coordinated MSF’s medical response to COVID-19 in the Navajo Nation, USA. At the Drugs for Neglected Diseases initiative (DNDi), she served as Head of Access and Medical Affairs, developing access frameworks for NTDs across Latin America. Currently, as Head of Global Health Affairs at Baraka Impact Finance, she supports social entrepreneurs in developing innovative health solutions. Dr. Batista also holds positions on the International Board of MSF and serves as a strategic advisor for ISGlobal

Research Interests

Dr. Carolina Batista’s research interests are deeply rooted in global health equity, focusing on neglected tropical diseases (NTDs), health systems in low- and middle-income countries, and access to healthcare for vulnerable populations. She is particularly interested in the development and implementation of innovative financing mechanisms to achieve the Sustainable Development Goals (SDGs), the role of private capital in bridging healthcare access gaps, and the integration of ethical artificial intelligence in health communication. Her work also explores the intersection of migration and health, pandemic preparedness, and the gender gap in healthcare access. Dr. Batista’s research aims to inform policies and practices that enhance healthcare delivery and accessibility for marginalized communities worldwide.

Research Skills

Dr. Carolina Batista possesses a robust set of research skills that encompass both qualitative and quantitative methodologies. Her expertise includes treatment protocols, health systems analysis, diagnostics, and primary care, particularly concerning parasitic and neglected diseases. She is adept at designing and implementing operational research projects, developing access frameworks, and conducting policy analysis. Her skills extend to evaluating health programs, engaging with stakeholders, and advocating for policy changes. Dr. Batista’s proficiency in these areas enables her to contribute effectively to research initiatives aimed at improving health outcomes in underserved populations.

Awards and Honors

Dr. Carolina Batista’s contributions to global health have been recognized through various appointments and memberships. She serves on the International Board of Médecins Sans Frontières (MSF) and is a strategic advisor for the Barcelona Institute for Global Health (ISGlobal). Her role in leading MSF’s medical response to COVID-19 in the Navajo Nation and her involvement in The Lancet COVID-19 Commission underscore her commitment to addressing health crises. Additionally, she chairs the DNDi Latin America board and serves on the boards of The Lancet Migration Latin America, Movement Health Foundation, and Health in Harmony. These positions reflect her leadership and dedication to advancing health equity and innovation.

Conclusion

Dr. Carolina Batista exemplifies a career dedicated to advancing global health equity through clinical practice, research, and policy development. Her extensive experience with organizations like MSF and DNDi, coupled with her strategic role at Baraka Impact Finance, highlights her commitment to improving healthcare access for marginalized populations. Her educational background and research interests inform her holistic approach to health challenges, integrating innovative solutions with traditional practices. Dr. Batista’s leadership roles and board memberships further demonstrate her influence in shaping global health policies and initiatives. Her work continues to inspire and drive progress towards equitable healthcare worldwide.

Publications Top Notes

1. Exposed Subsoil Under Recovery for 30 Years: Influence of Management Strategies on Soil Physical Attributes and Organic Matter

  • Authors: Laura Silva Nantes, Carolina dos Santos Batista Bonini, Melissa Alexandre Santos, Lucas da Silva Alves, Josiane Lourencetti, Alfredo Bonini Neto, José Augusto Liberato de Souza, Gabriel Augusto da Silva Lunardelli, Mariana Bonini Silva, Dayara Vivian Alvares, et al.

  • Year: 2025

2. Accumulated Carbon Fractions in Tropical Sandy Soils and Their Effects on Fertility and Grain Yield in an Integrated Crop–Livestock System

  • Authors: Deyvison de Asevedo Soares, Bianca Midori Souza Sekiya, Viviane Cristina Modesto, Allan Hisashi Nakao, Leandro Alves Freitas, Isabela Malaquias Dalto de Souza, J.H.S. Luz, Fernando Shintate Galindo, Gelci Carlos Lupatini, Gustavo Pavan Mateus, et al.

  • Year: 2023

3. Evolution of Soil Chemical Fertility in an Area under Recovery for 30 Years with Anthropic Intervention

  • Authors: Josiane Lourencetti, Carolina dos Santos Batista Bonini, Marcelo Andreotti, Marlene Cristina Alves, Alfredo Bonini Neto, Melissa Alexandre Santos, Vitor Correa de Mattos Barretto, Roberth Wicleff Rodrigues de Figueredo

  • Year: 2023

4. Long-Term Integrated Systems of Green Manure and Pasture Significantly Recover the Macrofauna of Degraded Soil in the Brazilian Savannah

  • Authors: Carolina dos Santos Batista Bonini, Thais Monique de Souza Maciel, Bruno Rafael de Almeida Moreira, José Guilherme Marques Chitero, Rodney Lúcio Pinheiro Henrique, Marlene Cristina Alves

  • Year: 2023

5. Long-Term Integrated Crop–Livestock–Forestry Systems Recover the Structural Quality of Ultisol Soil

  • Authors: Aline Matos, Carolina dos Santos Batista Bonini, Bruno Rafael de Almeida Moreira, Marcelo Andreotti, Reges Heinrichs, Diogo Tiago da Silva, José Augusto Liberato de Souza, Melissa Alexandre Santos, Cristiana Andrighetto, Gustavo Mateus Pavan, et al.

  • Year: 2022

6. Azospirillum Inoculation of ‘Marandu’ Palisade Grass Seeds: Effects on Forage Production and Nutritional Status

  • Authors: Reges Heinrichs, G.C. Meirelles, L.F. de Melo Santos, M.V. da Silva Lira, A. de Marcos Lapaz, M.A. Nogueira, C. dos Santos Batista Bonini, Filho, A. Moreira

  • Year: 2020

7. Can Palisade and Guinea Grass Sowing Time in Intercropping Systems Affect Soybean Yield and Soil Chemical Properties?

  • Authors: N.R. Costa, Marcelo Andreotti, C.A.C. Crusciol, C.M. Pariz, J.W. Bossolani, A.M.D. Castilhos, C.A.C.D. Nascimento, C.G.D.R. Lima, C. dos Santos Batista Bonini, E.E. Kuramae

  • Year: 2020

8. Effect of Sulfur Sources on Megathyrsus Maximus ‘Mombaça’ Grass Cultivated in a Typic Ultisol

  • Authors: L.F. de Melo Santos, A. de Marcos Lapaz, F.V. Ribeiro, I.V. Ribeiro, G.C. Meirelles, M.V. da Silva Lira, C.V. Soares Filho, C. dos Santos Batista Bonini, A.R. dos Reis, A. Moreira, et al.

  • Year: 2020

9. Soil Compaction in Crop-Livestock-Forest Integration Systems of Five Years of Implantation and Use

  • Authors: J.F.D. Souza, C. dos Santos Batista Bonini, G.P. Mateus, C.T. de Souza, R.L.S. Perusso, F.G. Pedro, G.L. Oliverio

  • Year: 2020

10. Spray Nozzles and Droplet Size Effects on Soybean Canopy Deposits and Stink Bugs Control in West Region of São Paulo State – Brazil

  • Authors: M.A.G.L. Farias, C.G. Raetano, R.G. Chechetto, P.J. Ferreira-Filho, J.C. Guerreiro, C.S.B. Bonini, A.C. Firmino, R.C. Lima, E.P. Prado

  • Year: 2020

​






	


	

	






	
	

		


Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award
			

				Published on  by WSA Awards			

		
	


	

		
Assoc. Prof. Dr. Yi-Ping Huang | Pharmaceutical Science | Women Researcher Award


Associate Professor from Department of Physiology, China Medical University, Taiwan




















Yi-Ping Huang is an accomplished Associate Professor in the Department of Physiology at China Medical University, with over 32 years of experience in both teaching and research. His primary focus is on cancer treatment, specifically investigating the therapeutic effects of natural and synthetic compounds on cancer cells. Over the years, Huang has significantly contributed to the field, publishing numerous peer-reviewed articles and advancing the understanding of cancer treatment mechanisms, particularly apoptosis, DNA damage, and anti-metastasis pathways. His expertise extends to drug synergy, especially in combination with chemotherapy. He has also been involved in teaching innovations in physiology, emphasizing student engagement and educational research. Huang’s extensive research output and leadership in the field have made him a well-respected figure in the scientific community, as reflected in his numerous research projects and academic publications.


Professional Profile



Education


Yi-Ping Huang completed his undergraduate studies in Physiology at Yang-Ming University, laying the foundation for his extensive career in research and academia. His academic journey provided a strong base for his research into cancer treatment and physiological mechanisms. This solid educational background enabled Huang to develop expertise in a range of specialized topics, particularly in the therapeutic effects of natural compounds. Over the years, his continuous learning and commitment to his field have propelled his success, making him an established academic in the study of cancer therapy and physiology.


Professional Experience


Yi-Ping Huang has a long and distinguished career in both academia and research. As an Associate Professor at China Medical University, he has been instrumental in educating students and conducting cutting-edge research on cancer therapy. With over three decades of experience, Huang has led numerous research projects focusing on natural and synthetic compounds in cancer treatment. His role also includes teaching and mentoring students, guiding them in the latest scientific advancements. Huang’s professional experience is marked by extensive publications in high-impact journals, further showcasing his contributions to the scientific community and his leadership in advancing cancer research.


Research Interests


Yi-Ping Huang’s primary research interests revolve around the use of natural and synthetic compounds in cancer therapy. His work explores the mechanisms through which these compounds induce apoptosis, DNA damage, and inhibit metastasis in cancer cells. Huang is particularly focused on understanding how these compounds can synergize with chemotherapy drugs to overcome resistance and improve treatment outcomes. His ongoing research also investigates the therapeutic effects of compounds such as Demethoxycurcumin (DMC), Phenethyl Isothiocyanate (PEITC), and PW06 in various cancer types, including glioblastoma and colon cancer. These areas of interest align with his goal of advancing cancer therapy through the identification and development of novel therapeutic agents.


Research Skills


Yi-Ping Huang’s research skills are extensive and diverse, ranging from molecular biology techniques to cancer therapy research. He possesses a deep understanding of cancer cell biology, particularly in apoptosis, DNA repair, and metastasis inhibition. Huang has demonstrated proficiency in the use of various experimental models to study the effects of natural and synthetic compounds on cancer cells, including in vitro and in vivo models. His expertise extends to studying drug interactions and mechanisms of drug resistance, especially in relation to chemotherapy. Huang’s interdisciplinary approach to research, combining pharmacology, molecular biology, and cancer therapy, has led to groundbreaking studies that have contributed significantly to the field.


Awards and Honors


Throughout his illustrious career, Yi-Ping Huang has received numerous awards and honors that recognize his contributions to the scientific community. His groundbreaking research in cancer therapy, particularly in the use of natural and synthetic compounds, has earned him accolades from academic institutions and scientific organizations. Huang’s work on compounds such as Demethoxycurcumin and Phenethyl Isothiocyanate has been widely recognized in the field of oncology research. His consistent contributions to cancer treatment research and his leadership in academia have earned him recognition as a leading expert in his field, enhancing his reputation as an influential figure in cancer research.


Conclusion


Yi-Ping Huang’s career has been defined by significant contributions to cancer research, particularly in the development and understanding of natural and synthetic compounds as therapeutic agents. His research focuses on the molecular mechanisms of apoptosis, DNA damage, and anti-metastasis, offering potential for groundbreaking advancements in cancer treatment. With over three decades of experience, Huang’s work continues to influence both basic and clinical cancer research. His leadership in academia, coupled with his innovative research, positions him as a respected figure in the scientific community. As he continues to push the boundaries of cancer therapy, his contributions are likely to have a lasting impact on the field.


Publication Top Notes


M084 causes cell cycle arrest and inhibits voltage-gated Na⁺ and K⁺ channels in neuronal N2A cells
Authors: Iat Lon Leong, Chinmin Chuang, Chenghsun Wu, Yukman Leung, Yiping Huang
Year: 2025


2. MCU-i4, a mitochondrial Ca²⁺ uniporter modulator, induces breast cancer BT474 cell death by enhancing glycolysis, ATP production and reactive oxygen species (ROS) burst
Authors: Edmund Cheung So, Louis Wing Cheong Chow, Chinmin Chuang, Yukman Leung, Yiping Huang
Year: 2025


3. Physalin A induces apoptosis through conjugating with Fas-FADD cell death receptor in human oral squamous carcinoma cells and suppresses HSC-3 cell xenograft tumors in NOD/SCID mice
Authors: Fu Shin Chueh, Shengyao Hsu, Kuangchi Lai, Yiping Huang, Wen Tsong Hsieh
Year: 2025


4. PEITC Induces DNA Damage and Inhibits DNA Repair-Associated Proteins in Human Retinoblastoma Cells In Vitro
Authors: Shengyao Hsu, Yiping Huang, Techun Hsia, Fu Shin Chueh, Chaolin Kuo
Year: 2024


5. Armillaria mellea Mycelia Alleviate PM2.5-Induced Pulmonary Inflammation in Murine Models
Authors: Yiping Huang, Yutsen Huang, Huiyu Wu, Chinchu Chen, Chih Ho Lai
Year: 2024


6. RAGE participates in the intracellular transport of Campylobacter jejuni cytolethal distending toxin
Authors: Yufang Chang, Yiping Huang, Chiahuei Chou, Chenghsun Chiu, Chih Ho Lai
Year: 2024
Citations: 2


7. PW06 suppresses cancer cell metastasis in human pancreatic carcinoma MIA PaCa-2 cells via the inhibitions of p-Akt/mTOR/NF-κB and MMP2/MMP9 signaling pathways in vitro
Authors: Yiping Huang, Chunan Yeh, Yishih Ma, Jin Cherng Lien, Wen Tsong Hsieh
Year: 2024
Citations: 2


























	


	

	






	
	

		


Sutha Devaraj | Pharmaceutical Science | Best Academic Researcher Award
			

				Published on  by WSA Awards			

		
	


	

		
Dr. Sutha Devaraj | Pharmaceutical Science | Best Academic Researcher Award


Deputy Dean from Perdana University, Malaysia 




















Sutha Devaraj is a dedicated researcher and academician with expertise in pharmaceutical sciences, specializing in drug discovery and pharmacology. She earned her Ph.D. in Pharmaceutical Sciences from Universiti Sains Malaysia (USM) in 2018, where her research focused on the development of optimized methods for preparing bioactive fractions of Strobilanthes crispus (L.) Bremek. Her work involved the quantification of the plant’s marker compound, contributing to advancements in natural product-based drug discovery. Before completing her Ph.D., Sutha obtained a Master’s in Pharmacology from USM in 2012. Her master’s thesis focused on the hepatoprotective properties of Curcuma xanthorrhiza Rox, exploring its potential for liver protection through its bioactive compounds. She also holds a B.Sc. (Hons) in Biotechnology from AIMST University, Malaysia, where she graduated with a CGPA of 3.41. This academic foundation in biotechnology provided her with a strong understanding of molecular biology and biochemistry, essential for her later research in pharmacology and drug development. Throughout her career, Sutha has contributed significantly to the study of plant-based compounds with medicinal properties, and her work has enhanced the understanding of their therapeutic potential. Her academic journey has been marked by a consistent focus on integrating practical research with innovative approaches in pharmaceutical sciences.


Professional Profile



Education






































Sutha Devaraj’s educational background is distinguished by her specialized studies in pharmaceutical sciences and pharmacology. She earned her Ph.D. in Pharmaceutical Sciences with a focus on Drug Discovery from Universiti Sains Malaysia (USM) in 2018. Her doctoral thesis, titled Development of an Optimized Method for the Preparation of Bioactive Fraction of Strobilanthes crispus (L.) Bremek and the Quantification of its Marker Compound, was instrumental in advancing research on bioactive compounds derived from natural sources. This work enhanced the understanding of the therapeutic potentials of Strobilanthes crispus, contributing to both pharmaceutical science and ethnomedicine. Before completing her Ph.D., Sutha obtained her Master of Science (M.Sc.) in Pharmacology from USM in 2012. Her research focused on the hepatoprotective and pharmacological properties of Curcuma xanthorrhiza Rox, and she published findings related to the effectiveness of its standardized ethanolic extract in protecting the liver, demonstrating her expertise in pharmacological testing and drug development. Sutha’s academic journey began with a Bachelor of Science (B.Sc.) in Biotechnology (Hons) from AIMST University in 2008, where she graduated with a CGPA of 3.41. This early foundation in biotechnology paved the way for her subsequent advanced studies in pharmacology and pharmaceutical sciences.


Professional Experience


Sutha Devaraj has accumulated significant experience in the field of pharmaceutical sciences and pharmacology. Throughout her career, she has worked with various academic and research institutions, where she has contributed to advancing the understanding of pharmacological mechanisms and drug discovery. As a researcher at Universiti Sains Malaysia (USM), Sutha has actively participated in projects focusing on the isolation and quantification of bioactive compounds from plants, which has led to important findings on their therapeutic potentials. She has collaborated with both local and international researchers to examine the pharmacological properties of natural products, a focus that has shaped her work in drug discovery. In addition to her research roles, Sutha has also contributed to teaching and mentoring undergraduate and postgraduate students. She has shared her expertise in pharmacology and biotechnology, helping shape the next generation of scientists. Through her work, Sutha has built a strong professional reputation, earning recognition for her in-depth understanding of drug development processes and her ability to implement novel methodologies in her research.


Research Skills


Sutha Devaraj possesses a wide array of research skills essential to her work in pharmaceutical sciences and pharmacology. Her proficiency in bioactive compound isolation and quantification has been demonstrated through her research on Strobilanthes crispus and Curcuma xanthorrhiza, both of which are significant to natural drug discovery. She is highly skilled in pharmacological testing, utilizing a range of in-vitro and in-vivo models to assess the therapeutic efficacy of plant-based extracts. In addition to her experimental capabilities, Sutha has expertise in analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry, which she has used to identify and quantify bioactive compounds in complex matrices. Her background in biotechnology provides her with a solid understanding of biochemical assays, including enzyme inhibition and receptor binding assays. Furthermore, Sutha has honed her skills in data analysis and interpretation, often using sophisticated statistical tools to evaluate research results. Her ability to combine these skills allows her to contribute to cutting-edge research in drug discovery, particularly in exploring new therapeutic agents derived from natural sources.


Research Interests


Sutha Devaraj’s research interests lie at the intersection of pharmacology, drug discovery, and natural products. She is particularly focused on the exploration of plant-based bioactive compounds and their potential applications in pharmaceutical development. Her Ph.D. research on Strobilanthes crispus exemplifies her dedication to the discovery of new therapeutic agents from natural resources. Sutha is passionate about investigating the hepatoprotective and anticancer properties of various plant species, particularly those indigenous to Southeast Asia. She is also interested in the mechanisms of action of these compounds, aiming to elucidate how they interact with biological systems to exert therapeutic effects. In addition to pharmacological studies, Sutha is keen on formulation development, specifically in optimizing methods for the preparation and stabilization of bioactive extracts. Her future research endeavors include furthering the development of natural-based drugs with fewer side effects compared to conventional synthetic drugs, contributing to a more sustainable and effective approach in pharmaceutical therapy.


Awards and Honors


Sutha Devaraj’s career has been marked by notable recognition for her academic and research contributions. She was awarded a PhD Fellowship by Universiti Sains Malaysia (USM), providing her with the opportunity to carry out high-impact research in the field of pharmaceutical sciences. Additionally, her M.Sc. research on Curcuma xanthorrhiza earned her accolades for its significance in hepatoprotective studies. Sutha’s ability to combine scientific rigor with practical applications has led to her work being published in well-respected, peer-reviewed journals. Her academic excellence and contributions to the field have earned her membership in several prestigious academic organizations and editorial positions in prominent journals related to pharmacology and drug development. Her work continues to be recognized by the academic community, highlighting her as an emerging leader in her field of expertise.


Conclusion


In conclusion, Sutha Devaraj is an accomplished researcher with a strong academic background and expertise in pharmacology and drug discovery. Her dedication to advancing natural product research has led to valuable contributions in the areas of bioactive compound isolation and pharmacological evaluation. Sutha’s research skills, which include advanced analytical techniques and experimental methodologies, equip her to make meaningful advances in the development of therapeutic agents. Her research interests reflect a deep commitment to exploring sustainable and effective natural-based drugs, particularly those with hepatoprotective and anticancer properties. With a growing reputation in the field, Sutha’s work continues to inspire innovation in the pharmaceutical sciences, and her achievements and contributions make her a prominent figure in the ongoing search for new, safer therapeutic options.


Publications Top Notes


1. Evaluation of the Antinociceptive Activity and Acute Oral Toxicity of Standardized Ethanolic Extract of the Rhizome of Curcuma xanthorrhiza Roxb


    

  • 

    Authors: S. Devaraj, A.S. Esfahani, S. Ismail, S. Ramanathan, M.F. Yam
    

    • 

  • 

    Journal: Molecules, 15(4), 2925–2934
    

    • 

  • 

    Year: 2010
    

    • 

  • 

    Citations: 97
    

    • 



2. Investigation of Antioxidant and Hepatoprotective Activity of Standardized Curcuma xanthorrhiza Rhizome in Carbon Tetrachloride‐Induced Hepatic Damaged Rats


    

  • 

    Authors: S. Devaraj, S. Ismail, S. Ramanathan, M.F. Yam
    

    • 

  • 

    Journal: The Scientific World Journal, 2014(1), 353128
    

    • 

  • 

    Year: 2014
    

    • 

  • 

    Citations: 75
    

    • 



3. Evaluation of the Hepatoprotective Activity of Standardized Ethanolic Extract of Curcuma xanthorrhiza Roxb


    

  • 

    Authors: S. Devaraj, S. Ismail, S. Ramanathan, S. Marimuthu, Y.M. Fei
    

    • 

  • 

    Journal: Journal of Medicinal Plants Research, 4(23), 2512–2517
    

    • 

  • 

    Year: 2010
    

    • 

  • 

    Citations: 53
    

    • 



4. Anti-Tumor Action, Clinical Biochemistry Profile and Phytochemical Constituents of a Pharmacologically Active Fraction of S. crispus in NMU-Induced Rat Model


    

  • 

    Authors: N.S. Yaacob, H.M. Yankuzo, S. Devaraj, J.K.M. Wong, C.S. Lai
    

    • 

  • 

    Journal: PLoS One, 10(5), e0126426
    

    • 

  • 

    Year: 2015
    

    • 

  • 

    Citations: 41
    

    • 



5. A Study on the Hepatoprotective Effect of Andrographis paniculata (Burm. F) Nees on Mice


    

  • 

    Author: D. Sutha
    

    • 

  • 

    Journal: Journal of Phytology, 2(11)
    

    • 

  • 

    Year: 2010
    

    • 

  • 

    Citations: 35
    

    • 



6. In Vivo Toxicological Investigations of Standardized Ethanolic Extract of Curcuma xanthorrhiza Roxb. Rhizome


    

  • 

    Authors: S. Devaraj, S. Ismail, S. Ramanathan, M. FeiYam
    

    • 

  • 

    Journal: Journal of Natural Products and Plant Resources, 3(1), 67–73
    

    • 

  • 

    Year: 2013
    

    • 

  • 

    Citations: 28
    

    • 



7. Explorations of CRISPR/Cas9 for Improving the Long-Term Efficacy of Universal CAR-T Cells in Tumor Immunotherapy


    

  • 

    Authors: M. Naeem, A. Hazafa, N. Bano, R. Ali, M. Farooq, S.I. Abd Razak, T.Y. Lee, et al.
    

    • 

  • 

    Journal: Life Sciences, 316, 121409
    

    • 

  • 

    Year: 2023
    

    • 

  • 

    Citations: 23
    

    • 



8. Phytochemical, Antioxidant, Antipyretic and Anti-inflammatory Activities of Aqueous-Methanolic Leaf Extract of Mangifera indica


    

  • 

    Authors: Q.U. Ain, M.O. Iqbal, I.A. Khan, N. Bano, M. Naeem, M.I. Jamaludin, S. Devaraj
    

    • 

  • 

    Journal: American Journal of Translational Research, 15(7), 4533
    

    • 

  • 

    Year: 2023
    

    • 

  • 

    Citations: 15
    

    • 



9. Pathogenetic Mechanisms of Liver-Associated Injuries, Management, and Current Challenges in COVID-19 Patients


    

  • 

    Authors: M. Naeem, N. Bano, S. Manzoor, A. Ahmad, N. Munawar, S.I.A. Razak, T.Y. Lee, et al.
    

    • 

  • 

    Journal: Biomolecules, 13(1), 99
    

    • 

  • 

    Year: 2023
    

    • 

  • 

    Citations: 10
    

    • 



10. Innovative Aspects and Applications of Single Cell Technology for Different Diseases


    

  • 

    Authors: A. Ali, S. Manzoor, T. Ali, M. Asim, G. Muhammad, A. Ahmad, M.I. Jamaludin, et al.
    

    • 

  • 

    Journal: American Journal of Cancer Research, 14(8), 4028
    

    • 

  • 

    Year: 2024
    

    • 

  • 

    Citations: 1
    

    • 



11. Understanding the Role of Pharmacology and Toxicology in the Research, Development, and Innovation Process by Analyzing the Drug Development Process


    

  • 

    Authors: L. Waheed, I. Ur Rehman, S. Devaraj, F.H.G.Q. Al-Amier, P. Jativa, G. Naz, et al.
    

    • 

  • 

    Journal: Journal of Pharmaceutical Negative Results, Vol. 14
    

    • 

  • 

    Year: 2023
    

    • 

  • 

    Citations: 1
    

    • 





























	


	

	






	
	

		


Niclas Nikolai Stephanson | Pharmaceutical Science | Best Researcher Award
			

				Published on  by WSA Awards			

		
	


	

		
Mr. Niclas Nikolai Stephanson | Pharmaceutical Science | Best Researcher Award


Scientist from Karolinska University Hospital, Sweden


Niclas Nikolai Stephanson is a seasoned clinical pharmacologist and forensic chemist based at the Karolinska University Hospital in Stockholm, Sweden. With a career spanning over three decades, he has carved out a notable reputation in the scientific community, particularly in the analysis of drugs of abuse. Holding a PhD in Medicine from the prestigious Karolinska Institutet, he combines academic rigor with practical experience. Niclas is a licensed pharmacist, senior chemist, and prolific researcher whose contributions include over 35 peer-reviewed scientific publications. His research focus lies at the intersection of pharmacology and toxicology, with a specialization in mass spectrometry and method development for detecting drugs in biological materials. He plays a pivotal role in improving clinical and forensic diagnostics through enhanced analytical techniques. Niclas’s work has contributed to better accuracy in detecting and quantifying illicit and therapeutic drugs, ultimately supporting public health and justice systems. His long-standing association with one of Europe’s most reputable hospitals is a testament to his dedication, expertise, and continuous contribution to the advancement of clinical pharmacology. Stephanson stands out not only for his technical skills but also for his impactful research that bridges laboratory science with real-world applications in healthcare and law enforcement.


Professional Profile



Education


Niclas Nikolai Stephanson received his academic training at the renowned Karolinska Institutet in Stockholm, Sweden, where he earned his PhD in Medicine in 2007. His doctoral work was rooted in the Department of Medicine and focused on the interdisciplinary field of clinical pharmacology, an area combining pharmacokinetics, pharmacodynamics, and toxicology. Prior to his doctoral studies, Niclas qualified as a licensed pharmacist, which provided him with a strong foundation in pharmaceutical sciences, drug interactions, and patient-centered pharmacotherapy. His dual academic background in pharmacy and medicine positions him at the nexus of research and clinical practice. This educational pathway has enabled him to integrate principles of chemistry, biology, and medicine in his professional work. Niclas’s academic experience at Karolinska Institutet—a globally respected institution known for its role in awarding the Nobel Prize in Physiology or Medicine—further highlights the high standards and intellectual rigor of his training. The comprehensive and multidisciplinary nature of his education has empowered him to design and conduct advanced analytical research while maintaining a deep understanding of clinical implications. Overall, his educational background has significantly influenced his ability to carry out complex method development and toxicological investigations with precision and clinical relevance.


Professional Experience


Niclas Nikolai Stephanson has been professionally affiliated with Karolinska University Hospital in Stockholm since August 1992, where he currently holds the position of Senior Chemist in the Department of Clinical Pharmacology. Over the span of more than three decades, he has contributed significantly to the hospital’s mission of delivering cutting-edge clinical diagnostics and therapeutic monitoring. As a licensed pharmacist and senior forensic chemist, Niclas has specialized in the analysis of drugs of abuse, playing a key role in the development and implementation of advanced analytical techniques for routine and investigational use. His daily responsibilities involve overseeing laboratory operations, mentoring junior staff, and collaborating with clinicians to interpret toxicological results. His long tenure reflects not only technical proficiency but also institutional trust in his expertise and leadership. Working within a hospital setting, he has consistently ensured that his research aligns with real-world clinical demands, particularly in the identification and quantification of illicit substances and medications in complex biological matrices. Stephanson’s role at Karolinska University Hospital also supports legal and forensic proceedings, as accurate drug analysis is crucial for both medical and judicial outcomes. His professional experience highlights a unique blend of scientific inquiry, clinical application, and public health impact.


Research Interests


Niclas Nikolai Stephanson’s research interests are centered on clinical pharmacology, forensic toxicology, and analytical chemistry, with a particular focus on the detection and analysis of drugs of abuse. He is especially committed to method development in toxicological screening, applying advanced techniques such as mass spectrometry to improve the precision and sensitivity of drug detection. His work often explores various biological matrices—ranging from blood and urine to less conventional materials like hair or oral fluid—to assess the presence and metabolism of illicit and therapeutic substances. Niclas’s interest in mass spectrometry enables the high-resolution identification of complex compounds, which is critical for timely and accurate diagnoses in both clinical and forensic settings. He is also interested in validating new protocols for routine use in healthcare facilities, aiming to bridge the gap between research and clinical practice. Additionally, his work contributes to public safety by improving methodologies used in legal and judicial drug testing. Through collaborations and internal projects at Karolinska University Hospital, his research continues to evolve in response to emerging substances and new analytical challenges. Overall, his interests reflect a strong alignment with societal needs in healthcare and law enforcement, emphasizing both scientific innovation and practical application.


Research Skills


Niclas Nikolai Stephanson possesses a robust set of research skills that underscore his success as a senior clinical chemist and academic contributor. One of his core strengths lies in advanced method development, particularly in the field of forensic toxicology, where he designs, tests, and refines techniques for detecting drugs of abuse in biological matrices. His proficiency in mass spectrometry—including LC-MS/MS and GC-MS systems—is central to his work, enabling precise identification and quantification of substances even in trace amounts. Niclas is also skilled in biological sample preparation, including extraction and purification techniques that are critical for ensuring reliable analytical results. He demonstrates strong data analysis and validation abilities, ensuring that his methods meet rigorous standards for reproducibility, sensitivity, and specificity. In addition, he has experience in regulatory compliance and quality assurance, ensuring that laboratory practices align with healthcare and forensic standards. His skill set extends to scientific writing and publication, as evidenced by his record of more than 35 peer-reviewed articles. These competencies, combined with his practical knowledge of clinical workflows, empower him to translate complex research into diagnostic and therapeutic tools. His research skills are not only technical but also strategic, aiming to meet real-world challenges with innovative scientific solutions.


Awards and Honors


Although specific awards or honors for Niclas Nikolai Stephanson are not explicitly listed, his sustained position at Karolinska University Hospital and the volume of his peer-reviewed publications are indicative of high professional recognition and esteem. Holding a senior chemist position at one of Europe’s leading medical institutions is a reflection of both his expertise and institutional trust in his abilities. His role in the department of Clinical Pharmacology implies consistent recognition through internal appointments, research responsibilities, and possibly departmental accolades for contributions to method development and toxicological analysis. Publishing over 35 scientific articles in peer-reviewed journals also suggests peer recognition and validation of his work within the scientific community. It is not uncommon in the medical sciences for researchers with such a track record to be involved in national and international working groups or to serve as peer reviewers or advisors in forensic and clinical pharmacology. His continued association with the Karolinska Institutet—home to Nobel-level research—implies a professional standing that exceeds routine recognition. While specific honors may not be documented publicly, his contributions and career longevity highlight a professional trajectory marked by consistent achievement and expert-level contribution to clinical science.


Conclusion


Niclas Nikolai Stephanson stands as a highly accomplished clinical pharmacologist and forensic chemist whose contributions span research, diagnostics, and public health. His work at Karolinska University Hospital since 1992, combined with a PhD from Karolinska Institutet, demonstrates a career dedicated to scientific excellence and societal impact. He has specialized in the development of analytical methods using mass spectrometry to detect drugs of abuse, contributing to over 35 peer-reviewed publications. His research not only enhances clinical decision-making but also supports forensic and legal systems by ensuring accurate and timely drug testing. While his achievements are impressive, expanding his international collaborations and diversifying his research themes could further amplify his academic influence. Nonetheless, his sustained excellence and deep specialization in clinical pharmacology make him a valuable asset to the scientific and medical community. Stephanson’s profile exemplifies the rare blend of research depth, clinical utility, and long-term dedication, positioning him as a strong candidate for prestigious honors such as the Best Researcher Award. His work bridges the gap between bench science and bedside application, marking him as a leader in toxicological innovation and a model for aspiring researchers in the field.


Publications Top Notes


    

  1. 

    Title: Application of liquid chromatography combined with high resolution mass spectrometry for urine drug testing
    Authors: O.M.L. Beck (Olof M.L.), A. Rylski (Alexia), N.N. Stephanson (Nikolai N.)
    Citations: 4
    

    2. 

  2. 

    Title: Use of LC–HRMS in full scan-XIC mode for multi-analyte urine drug testing – a step towards a ‘black-box’ solution?
    Authors: N.N. Stephanson (Nikolai N.), P. Signell (Patrick), A. Helander (Anders), O.M.L. Beck (Olof M.L.)
    Year: 2017
    Citations: 19
    

    3. 




	


	

	






	
	

		


Eman Zahran | Pharmaceutical Science | Best Academic Researcher Award
			

				Published on  by WSA Awards			

		
	


	

		
Assoc. Prof. Dr. Eman Zahran | Pharmaceutical Science | Best Academic Researcher Award


Associate Professor of Pharmacognosy from Deraya university, Egypt


Dr. Eman Maher Zahran is a distinguished academic and researcher in the field of pharmacognosy, currently serving as an Associate Professor at Deraya University’s Faculty of Pharmacy. With a career rooted in natural product research, her work spans the morphological study of medicinal plants to the biological activities of phytoconstituents. A Ph.D. graduate from Minia University, she has demonstrated unwavering commitment to academic excellence, scientific innovation, and student mentorship. Her research integrates traditional knowledge with advanced technologies such as metabolomic profiling, ESI-HR-MS analysis, and molecular docking. Dr. Zahran has authored over 25 impactful peer-reviewed articles and delivered talks at key international and national pharmaceutical conferences. In addition to her scholarly contributions, she is actively involved in student-centered initiatives, scientific committees, and governmental outreach programs. Her editorial and peer-review work across several international journals further amplifies her impact within the global scientific community. A strong advocate for female leadership in science, she completed the prestigious “The Woman Leads” program at Egypt’s National Training Academy. Dr. Zahran’s blend of academic excellence, innovative research, leadership in community engagement, and dedication to advancing pharmacognosy education positions her as a leading figure in Egypt’s pharmaceutical sciences landscape.


Professional Profile



Education


Dr. Eman Maher Zahran’s educational journey is deeply rooted in Minia University, where she pursued her undergraduate, master’s, and doctoral degrees in Pharmaceutical Sciences with a specialization in Pharmacognosy. She completed her B.Sc. in Pharmaceutical Sciences in 2006 with a cumulative grade of “Very Good.” Her keen interest in medicinal plants and natural product research led her to undertake pre-master courses in 2007, which served as the foundation for her M.Sc. that spanned from 2007 to 2013. Her master’s research involved the detailed phytochemical investigation of plant constituents and their pharmacological evaluation. From 2016 to 2020, she pursued her Ph.D. at the Faculty of Pharmacy, Minia University, where she delved into advanced areas such as metabolomics, molecular docking, and structure elucidation of phytoconstituents. Her doctoral work not only reflected technical expertise but also interdisciplinary collaboration. During this academic trajectory, she also completed specialized training programs and participated in scientific workshops that refined her methodological capabilities. The strength of her education lies in its comprehensive nature, encompassing foundational knowledge, research techniques, and a critical understanding of the pharmacological potential of natural compounds, all of which have laid the groundwork for her ongoing contributions to pharmaceutical research and academia.


Professional Experience


Dr. Zahran’s professional trajectory reflects a steady and strategic ascent through the academic ranks of pharmacognosy. She began her journey as a community pharmacist, transitioning into academia in 2008 as a postgraduate researcher and then as a teaching assistant. Between 2010 and 2012, she served as a grant teaching assistant for Clinical Pharmacy students. From 2016 to 2020, she was appointed Associate Lecturer at the Faculty of Pharmacy, Minia University. In 2020, she was promoted to Assistant Professor, where she continued to lead educational initiatives, mentor students, and develop curricula. As of March 2025, she holds the rank of Associate Professor at Deraya University. Dr. Zahran has also been deeply involved in co-curricular activities, supervising multiple student-led initiatives such as “Hayah,” a student entity focused on scientific and community outreach. She has contributed to post-graduate course development and served on Deraya’s Quality Assurance and Accreditation Unit. Her participation in national-level training programs like “The Woman Leads” demonstrates her leadership and civic engagement. With over 15 years of diverse experience spanning pharmacy practice, teaching, and research, Dr. Zahran has emerged as a dynamic academic professional, recognized for her commitment to excellence, innovation, and interdisciplinary collaboration.


Research Interests


Dr. Zahran’s research interests center on pharmacognosy and natural product chemistry, with a strong emphasis on isolating, identifying, and evaluating bioactive phytoconstituents derived from medicinal plants and marine algae. Her work integrates classical botanical techniques with cutting-edge technologies like ESI-HR-MS analysis and molecular docking. A unique aspect of her research involves the application of network pharmacology to uncover the multi-target mechanisms of natural compounds, especially in treating complex disorders like ADHD and osteoarthritis. Her contributions extend to investigating the wound healing, antifungal, antiplasmodial, and anti-inflammatory properties of various natural substances. Recently, she has delved into combining natural phytochemicals with stem cell therapies to enhance regenerative medicine applications. Additionally, Dr. Zahran’s studies examine the environmental and biochemical effects of phytoconstituents using in vitro, in vivo, and in silico models. This holistic and multidisciplinary approach allows her to bridge the gap between traditional herbal medicine and contemporary pharmacological science. Her interest in neuropsychiatric disorders also reflects a forward-thinking orientation, exploring novel therapeutic avenues. Through her robust pipeline of projects and publications, she continues to identify plant-based compounds with the potential to be developed into pharmaceutical agents, contributing significantly to both academic knowledge and practical healthcare innovation.


Research Skills


Dr. Eman Maher Zahran is equipped with an extensive set of research skills that make her a leading expert in pharmacognosy and natural product research. She is proficient in the morphological and micromorphological analysis of medicinal plants and marine algae, with deep expertise in isolation and structure elucidation techniques for phytochemicals. Her methodological proficiency spans thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC), and advanced mass spectrometric techniques, including ESI-HR-MS. Furthermore, she demonstrates high competence in molecular docking, network pharmacology, and in silico ADME studies, which she integrates seamlessly into phytochemical investigations. Dr. Zahran is also skilled in conducting both in vitro and in vivo biological activity assessments, exploring pharmacodynamics and pharmacokinetics of bioactive compounds. Her research frequently employs interdisciplinary approaches, such as combining plant extracts with mesenchymal stem cells in regenerative medicine models. Additionally, she is adept in scientific writing and publishing, having authored numerous high-impact papers in Scopus-indexed and Web of Science journals. Her peer-review activities and editorial board membership further reflect her critical appraisal capabilities. Collectively, her skills not only underscore her technical competence but also her innovative spirit and dedication to producing translational research that advances healthcare through natural product pharmacology.


Awards and Honors


Dr. Eman Maher Zahran has garnered significant recognition for her academic achievements, both within her institution and the broader scientific community. She was honored by Deraya University for her outstanding academic contributions from 2020 onward, a period during which she published prolifically and advanced numerous research projects. Her active role in student development and community outreach, particularly through her supervision of the “Hayah” entity and ADHD-focused conferences, highlights her multifaceted impact. In 2023, she was selected to join the second cohort of the Egyptian National Training Academy’s “The Woman Leads” program, which is designed to empower and equip promising female leaders in science and education. She serves as an editorial board member and peer reviewer for multiple prestigious journals, including the Journal of Pharmaceutical Chemistry & Chemical Science, Octahedron Drug Research, and journals by the Royal Society of Chemistry. Furthermore, her selection to the scientific committee of international congresses on nanoscience and pharmacology reflects her expertise and respected standing in the academic community. These honors not only affirm her scientific merit but also her leadership, dedication to knowledge dissemination, and her influential role in shaping the future of pharmacognosy in Egypt and beyond.


Conclusion


Dr. Eman Maher Zahran exemplifies the qualities of a dedicated academic, an innovative researcher, and an inspiring mentor. Her career is marked by a relentless pursuit of excellence, from foundational studies in pharmaceutical sciences to cutting-edge research in natural product pharmacology. Her interdisciplinary focus—combining phytochemistry, molecular modeling, and regenerative medicine—demonstrates her commitment to translating traditional medicinal knowledge into therapeutic breakthroughs. Dr. Zahran’s engagement with students, leadership in research committees, and active role in scientific communication reflect her holistic academic persona. Her prolific publication record, participation in international conferences, and collaborations underscore her relevance on both national and global levels. Equally commendable is her devotion to community-based initiatives, particularly in raising awareness and support for neuropsychiatric conditions like ADHD. Her recognition through institutional awards and national leadership programs stands as a testament to her impact. As she continues to expand her research footprint and inspire the next generation of scientists, Dr. Zahran remains a vital force in the advancement of pharmacognosy and pharmaceutical sciences. Her contributions resonate far beyond the laboratory and classroom, positioning her as a role model and a key influencer in the evolving landscape of academic research and community health promotion.


Publications Top Notes


    

  • 

    Title: Diversity, phytochemical and medicinal potential of the genus Ocimum L. (Lamiaceae)
    Authors: EM Zahran, UR Abdelmohsen, HE Khalil, SY Desoukey, MA Fouad, …
    Year: 2020
    Citations: 86
    

    • 

  • 

    Title: Bioactivity potential of marine natural products from scleractinia-associated microbes and in silico anti-SARS-COV-2 evaluation
    Authors: EM Zahran, A Albohy, A Khalil, AH Ibrahim, HA Ahmed, EM El-Hossary, …
    Year: 2020
    Citations: 41
    

    • 

  • 

    Title: Antioxidant and wound healing potential of Vitis vinifera seeds supported by phytochemical characterization and docking studies
    Authors: T Al-Warhi, EM Zahran, S Selim, MM Al-Sanea, MM Ghoneim, SA Maher, …
    Year: 2022
    Citations: 36
    

    • 

  • 

    Title: Multitarget in silico studies of Ocimum menthiifolium, family Lamiaceae against SARS-CoV-2 supported by molecular dynamics simulation
    Authors: A Albohy, EM Zahran, UR Abdelmohsen, MA Salem, T Al-Warhi, …
    Year: 2022
    Citations: 29
    

    • 

  • 

    Title: Antiulcer potential and molecular docking of flavonoids from Ocimum forskolei Benth., family Lamiaceae
    Authors: EM Zahran, UR Abdelmohsen, AS Hussein, MA Salem, HE Khalil, …
    Year: 2021
    Citations: 27
    

    • 

  • 

    Title: Scabicidal potential of coconut seed extract in rabbits via downregulating inflammatory/immune cross talk: A comprehensive phytochemical/GC-MS and in silico proof
    Authors: EM Zahran, NMR Abdel-Maqsoud, OY Tammam, IM Abdel-Rahman, …
    Year: 2022
    Citations: 23
    

    • 

  • 

    Title: New Acaciin-loaded self-assembled nanofibers as MPro inhibitors against BCV as a surrogate model for SARS-CoV-2
    Authors: SA Mohamad, EM Zahran, MR Abdel Fadeel, A Albohy, MA Safwat
    Year: 2021
    Citations: 23
    

    • 

  • 

    Title: New halogenated compounds from Halimeda macroloba seaweed with potential inhibitory activity against malaria
    Authors: AH Elmaidomy, EM Zahran, R Soltane, A Alasiri, H Saber, CJ Ngwa, …
    Year: 2022
    Citations: 22
    

    • 

  • 

    Title: Metabolic profiling, histopathological anti-ulcer study, molecular docking and molecular dynamics of ursolic acid isolated from Ocimum forskolei Benth. (family Lamiaceae)
    Authors: EM Zahran, UR Abdelmohsen, AT Ayoub, MA Salem, HE Khalil, …
    Year: 2020
    Citations: 21
    

    • 

  • 

    Title: Cytotoxic and anti-diabetic potential, metabolic profiling and in silico studies of Syzygium cumini (L.) Skeels belonging to family Myrtaceae
    Authors: SS Eldin Elhawary, AE Elmotayam, D Alsayed, EM Zahran, MA Fouad, …
    Year: 2022
    Citations: 11
    

    •